AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca’s latest clinical study, titled ‘ATHENA,’ is a Phase I/II open-label trial aimed at evaluating the safety and efficacy of AZD5851, a CAR-T cell therapy targeting GPC3, in adults with advanced or recurrent hepatocellular carcinoma. This study is significant as it explores a novel treatment option for patients who have not responded to previous therapies.
The intervention being tested is AZD5851, a biological therapy designed to target and destroy cancer cells expressing the GPC3 protein. It involves the use of CAR-T cells, which are engineered to enhance the immune system’s ability to fight cancer.
The study follows an interventional design with a single-group model, meaning all participants receive the same treatment. There is no masking, as it is an open-label trial, and the primary purpose is treatment-focused.
The study commenced on December 14, 2023, with the latest update submitted on July 7, 2025. These dates are crucial as they mark the study’s progress and the timeline for potential data availability.
This update could positively influence AstraZeneca’s stock performance by showcasing their commitment to innovative cancer therapies. Investors might view this as a promising development in the competitive oncology market, potentially enhancing investor sentiment.
The ATHENA study is ongoing, with further details available on the ClinicalTrials portal.